Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLPT NASDAQ:CVRX NASDAQ:LUNG NYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$11.38+0.4%$12.22$6.25▼$19.22$318.52M0.92260,651 shs351,702 shsCVRXCVRx$8.35-1.2%$6.37$4.30▼$18.55$217.71M1.23307,672 shs538,904 shsLUNGPulmonx$3.09+6.2%$3.00$2.50▼$9.37$124.40M0.45313,927 shs486,731 shsNSPRInspireMD$2.41+3.0%$2.40$1.99▼$3.80$73.83M0.5769,447 shs52,412 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+1.61%-7.43%-2.33%-7.43%+49.28%CVRXCVRx+19.01%+21.41%+43.71%+35.20%-14.73%LUNGPulmonx+7.78%+6.59%-2.35%-35.62%-63.16%NSPRInspireMD+1.74%-3.70%-4.49%-9.65%-4.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLPTClearPoint Neuro1.8506 of 5 stars3.51.00.00.02.40.80.6CVRXCVRx3.0804 of 5 stars3.41.00.00.03.44.20.6LUNGPulmonx3.4374 of 5 stars3.35.00.00.02.03.30.6NSPRInspireMD2.8111 of 5 stars3.53.00.00.01.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro 3.00Buy$25.00119.68% UpsideCVRXCVRx 2.86Moderate Buy$14.5073.65% UpsideLUNGPulmonx 2.63Moderate Buy$11.53272.98% UpsideNSPRInspireMD 3.00Buy$4.5086.72% UpsideCurrent Analyst Ratings BreakdownLatest NSPR, CLPT, CVRX, and LUNG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2025CVRXCVRxWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.005/9/2025CVRXCVRxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.005/9/2025CVRXCVRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.005/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$32.24M9.88N/AN/A$0.92 per share12.37CVRXCVRx$52.87M4.12N/AN/A$2.93 per share2.85LUNGPulmonx$83.79M1.48N/AN/A$2.17 per share1.42NSPRInspireMD$7.03M10.51N/AN/A$1.83 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$18.91M-$0.76N/AN/AN/A-64.51%-78.09%-51.33%8/6/2025 (Estimated)CVRXCVRx-$59.97M-$2.18N/AN/AN/A-97.49%-79.04%-42.37%8/4/2025 (Estimated)LUNGPulmonx-$56.39M-$1.44N/AN/AN/A-65.27%-63.69%-34.94%7/30/2025 (Estimated)NSPRInspireMD-$19.92M-$0.79N/AN/AN/A-413.96%-69.42%-57.68%N/ALatest NSPR, CLPT, CVRX, and LUNG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025CLPTClearPoint Neuro-$0.20N/AN/AN/A$9.20 millionN/A8/4/2025Q2 2025CVRXCVRx-$0.52N/AN/AN/AN/AN/A7/30/2025Q2 2025LUNGPulmonx-$0.40N/AN/AN/A$23.46 millionN/A5/13/2025Q1 2025CLPTClearPoint Neuro-$0.15-$0.22-$0.07-$0.22$8.21 million$8.49 million5/8/2025Q1 2025CVRXCVRx-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/ACVRXCVRxN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint NeuroN/A3.532.57CVRXCVRx0.7114.8213.45LUNGPulmonx0.384.974.29NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%CVRXCVRx75.27%LUNGPulmonx91.04%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro6.97%CVRXCVRx13.90%LUNGPulmonx6.80%NSPRInspireMD34.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro11027.99 million26.04 millionOptionableCVRXCVRx16026.07 million22.45 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionableNSPRInspireMD5030.64 million18.33 millionOptionableNSPR, CLPT, CVRX, and LUNG HeadlinesRecent News About These CompaniesInspireMD Launches CGuard Prime Carotid Stent System in the U.S.July 11, 2025 | zacks.comInspireMD’s CGuard Prime Carotid Stent System Launched in United StatesJuly 10, 2025 | evtoday.comEInspireMD stock rises after US commercial launch of carotid stent systemJuly 10, 2025 | au.investing.comInspireMD launches carotid stent in U.S. after FDA approvalJuly 10, 2025 | massdevice.comInspireMD Shares Rise on U.S. Rollout of CGuard Prime Carotid StentJuly 10, 2025 | msn.comInspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of StrokeJuly 9, 2025 | globenewswire.comInspireMD, Inc. (NSPR) Latest Stock News & Headlines - Yahoo FinanceJuly 5, 2025 | finance.yahoo.comHuntleigh Advisors Inc. Makes New $316,000 Investment in InspireMD, Inc. (NYSE:NSPR)July 5, 2025 | marketbeat.comInspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke - MorningstarJune 26, 2025 | morningstar.comMInspireMD Inc.: InspireMD Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of StrokeJune 25, 2025 | finanznachrichten.deFDA grants PMA for InspireMD CGuard Prime carotid stent, triggers $18M milestone paymentJune 25, 2025 | massdevice.comInspireMD Stock Surges on FDA Approval for CGuard StentJune 24, 2025 | marketwatch.comInspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of StrokeJune 24, 2025 | globenewswire.comInspireMD CGuard Prime EPS Carotid Stent System Receives CE Mark ApprovalJune 16, 2025 | evtoday.comEInspireMD Announces CE Mark Approval For CGuard Prime Embolic Prevention SystemJune 15, 2025 | nasdaq.comInspireMD, Inc. Secures CE Mark Approval for CGuard® Prime EPS Carotid Stent SystemJune 15, 2025 | nasdaq.comInspireMD wins CE Mark approval for CGuard PrimeJune 13, 2025 | massdevice.comInspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of StrokeJune 13, 2025 | globenewswire.comInspireMD Hires New Financial ChiefJune 4, 2025 | marketwatch.comInspireMD appoints Michael Lawless CFOJune 4, 2025 | msn.comInspireMD Announces Appointment of Michael Lawless as Chief Financial OfficerJune 3, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNSPR, CLPT, CVRX, and LUNG Company DescriptionsClearPoint Neuro NASDAQ:CLPT$11.38 +0.05 (+0.44%) Closing price 04:00 PM EasternExtended Trading$11.42 +0.04 (+0.35%) As of 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.CVRx NASDAQ:CVRX$8.35 -0.10 (-1.18%) Closing price 04:00 PM EasternExtended Trading$8.36 +0.01 (+0.06%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Pulmonx NASDAQ:LUNG$3.09 +0.18 (+6.19%) Closing price 04:00 PM EasternExtended Trading$3.12 +0.03 (+0.97%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.InspireMD NYSE:NSPR$2.41 +0.07 (+2.99%) Closing price 04:00 PM EasternExtended Trading$2.42 +0.01 (+0.41%) As of 04:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now Citigroup Earnings Could Signal What’s Next for Markets This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
